Information Provided By:
Fly News Breaks for February 7, 2018
ICPT
Feb 7, 2018 | 06:14 EDT
Goldman Sachs analyst Salveen Richter downgraded Intercept Pharmaceuticals to Sell and cut his price target for the shares to $45 from $74. The analyst sees a lack of catalyats to move the stock higher. Intercept closed yesterday up $2.08 to $60.82.
News For ICPT From the Last 2 Days
There are no results for your query ICPT